Thursday, November 21, 2024
11/21/2024
Project Summary Alzheimer’s disease (AD) is a neurodegenerative disorder that culminates in neurodegeneration resulting in cognitive decline. The pathological correlate most tightly associated with cognitive decline in AD is synapse loss. Synaptic loss occurs in early-stage AD patients and progresses over time. The presence of pathological tau significantly correlates with synapse loss and cognitive decline in AD, and synapse loss is present in all models of tauopathy. It is unclear how pathological tau causes synapse loss, however neuroinflammation, including activation of microglia and the complement cascade, may play a causative role. The complement system, and specifically complement C1q, is used by the central nervous system to coordinate the removal of synapses. Within the brain, complement C1q coats the membrane of weak or damaged synapses, resulting in phagocytic removal of tagged synapses by microglia. In the AD brain there is an increase in C1q-mediated synaptic pruning resulting in synapse loss. Importantly, complement activation and synapse loss correlate with the deposition of pathological tau. We hypothesize that a tau-induced insult initiates a synaptic profile that attracts C1q to coat synapses for removal. The mechanisms by which C1q recognizes tau-affected synapses are unclear. Synaptic deposition of C1q requires presentation of a C1q-binding partner in the outer membrane of weak/damaged synapses. In addition, cells normally express complement regulatory proteins that prevent the synaptic deposition of C1q. Thus, tau-induced synaptic changes that recruit C1q to the synaptic membrane could include 1) the presentation of disease-specific C1q binding partners, and/or 2) a decrease in the expression of complement inhibitory regulators. We will investigate both possibilities in the PS19 mouse model of tauopathy. To identify potential C1q interacting partners, synaptosomes will be isolated from the hippocampus of PS19 or wild type (WT) mice and C1q will be immunoprecipitated from synaptosomes. Mass spectrometry will be used to identify protein and lipid interacting partners that co- immunoprecipitate with C1q. C1q interacting partners identified by mass spec will be verified biochemically and histologically in PS19 mice and early-stage post-mortem human AD tissue. To determine the effect of tauopathy on synaptic complement regulatory proteins, we will isolate C1q+ synaptosomes from PS19 or WT mice at 1, 3 and 6 months of age and quantify complement regulators. Changes in complement regulators will be correlated to changes in pathological tau. Changes in complement regulators in PS19 mice will be confirmed in early-stage post-mortem human AD tissue. Successful completion of these aims will identify the molecular mechanisms of complement mediated synaptic pruning in response to tauopathy. Preventing synaptic loss in early-stage AD patients could preserve cognitive function and improve quality of life.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).
